Huya Bioscience International LLC has raised $48 million in debt financing, according to a recent filing with the Securities and Exchange Commission.
The company is involved in the global development of novel biopharmaceutical products originating in China. According to the company’s website, Huya has established extensive collaborations with Chinese biopharmaceutical academic and commercial organizations to speed development and value creation in worldwide markets for China-sourced product candidates.
Huya has offices in the United Kingdom, Japan and in eight strategic locations across China, with joint headquarters in San Diego and Shanghai.
The company did not respond to a request for comment on the use proceeds. According to the SEC, Huya filed the new Form D on April 22, 2015, but disclosed that the first date of sale was Sept. 27, 2013.